Log in

NASDAQ:XENT - Intersect ENT Stock Price, Forecast & News

$21.11
-0.29 (-1.36 %)
(As of 12/8/2019 04:23 AM ET)
Today's Range
$21.10
Now: $21.11
$21.55
50-Day Range
$16.66
MA: $20.27
$22.01
52-Week Range
$14.61
Now: $21.11
$35.87
Volume339,335 shs
Average Volume374,151 shs
Market Capitalization$665.28 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Intersect ENT, Inc, a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENT
CUSIPN/A
Phone650-641-2100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$108.47 million
Book Value$3.96 per share

Profitability

Net Income$-22,920,000.00

Miscellaneous

Employees393
Market Cap$665.28 million
Next Earnings Date2/24/2020 (Estimated)
OptionableOptionable

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.


Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

How were Intersect ENT's earnings last quarter?

Intersect ENT Inc (NASDAQ:XENT) announced its quarterly earnings data on Friday, November, 1st. The medical equipment provider reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.01. The medical equipment provider had revenue of $24.06 million for the quarter, compared to the consensus estimate of $24.08 million. Intersect ENT had a negative return on equity of 34.19% and a negative net margin of 36.37%. The business's revenue for the quarter was down 2.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.25) earnings per share. View Intersect ENT's Earnings History.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Intersect ENT.

What price target have analysts set for XENT?

8 analysts have issued 12 month price objectives for Intersect ENT's shares. Their forecasts range from $20.00 to $40.00. On average, they expect Intersect ENT's stock price to reach $27.13 in the next year. This suggests a possible upside of 28.5% from the stock's current price. View Analyst Price Targets for Intersect ENT.

What is the consensus analysts' recommendation for Intersect ENT?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 7 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intersect ENT.

What are Wall Street analysts saying about Intersect ENT stock?

Here are some recent quotes from research analysts about Intersect ENT stock:
  • 1. Northland Securities analysts commented, "We are upgrading Intersect ENT to a Market Perform rating. We had downgraded the stock immediately after the Q1 report. The stock has reached our price target, hence the ratings change. We note though, the ratings change does not reflect a fundamental change in outlook, at least for now." (7/10/2019)
  • 2. According to Zacks Investment Research, "Over the past year, shares of Intersect ENT have underperformed the industry it belongs to. Escalating costs and expenses continue to weigh on the company’s margins. This apart, the pricing scenario is persistently tough for Intersect ENT. Strong competitors in the large medical device market also pose a tough challenge. On a positive note, within a short span of time, the SINUVA line of business has made a considerable progress with market access and field force balance. Within the company’s Propel line, Intersect ENT registered 10% growth in the top line during the fourth quarter 2018, driven by an expanded usage of Contour among both the current as well as the new physicians." (5/3/2019)
  • 3. BTIG Research analysts commented, "Intersect reported Q4 revenue in line with its preannouncement. Guidance of $123M-$127M (also given previously) remains just below the Street’s $127.2M but not surprising given some conservatism early in the year. The company will no longer guide SINUVA but is aware of Street estimates and will see how sales play out. The big surprise was operating expense guidance of $135-137M which was well above most estimates. We think shares will be pressured Tuesday. While a good portion of this increased spend will be R&D for a new drug-coated balloon, it is also clear that much of XENT’s growth is coming through head count. While Intersect will have significantly more data coming, we continue to remain cautious around reimbursement for SINUVA. We do not know what will happen with the re- proposed J-Code and we are not sure how many insurance companies will decide to pay more than once per year." (2/26/2019)

Has Intersect ENT been receiving favorable news coverage?

Media stories about XENT stock have been trending somewhat positive this week, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Intersect ENT earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Intersect ENT.

Are investors shorting Intersect ENT?

Intersect ENT saw a drop in short interest in the month of October. As of October 31st, there was short interest totalling 1,400,000 shares, a drop of 13.6% from the September 30th total of 1,620,000 shares. Based on an average trading volume of 384,700 shares, the short-interest ratio is presently 3.6 days. Currently, 4.6% of the company's stock are short sold. View Intersect ENT's Current Options Chain.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the folowing people:
  • Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
  • Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
  • Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
  • Ms. Christine R. Kowalski, Chief Operations Officer (Age 62)

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a number of of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (6.41%), State Street Corp (2.31%), Man Group plc (2.09%), Assenagon Asset Management S.A. (0.41%), State of New Jersey Common Pension Fund D (0.36%) and California State Teachers Retirement System (0.15%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt, Richard E Kaufman, Robert H Binney, Jr and Susan P Stimson. View Institutional Ownership Trends for Intersect ENT.

Which major investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Endurant Capital Management LP, Boston Advisors LLC and SG Americas Securities LLC. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Robert H Binney, Jr and Susan P Stimson. View Insider Buying and Selling for Intersect ENT.

Which major investors are buying Intersect ENT stock?

XENT stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, State Street Corp, Man Group plc, Nisa Investment Advisors LLC, California Public Employees Retirement System, Quadrant Capital Group LLC and California State Teachers Retirement System. View Insider Buying and Selling for Intersect ENT.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $21.11.

How big of a company is Intersect ENT?

Intersect ENT has a market capitalization of $665.28 million and generates $108.47 million in revenue each year. The medical equipment provider earns $-22,920,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.View Additional Information About Intersect ENT.

What is Intersect ENT's official website?

The official website for Intersect ENT is http://www.intersectent.com/.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]


MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  367 (Vote Outperform)
Underperform Votes:  256 (Vote Underperform)
Total Votes:  623
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Featured Article: Market Capitalization

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel